Professional Documents
Culture Documents
Australian
Rheumatology
Association
HYDROXYCHLOROQUINE
(Brand name: Plaquenil)
hydroxychloroquine
What is hydroxychloroquine?
Hydroxychloroquine (brand name
Plaquenil) is a medicine used to treat
rheumatoid arthritis and other inflammatory
conditions such as systemic lupus
erythematosus (SLE/Lupus).
Hydroxychloroquine is also an antimalarial
medicine used to prevent and treat malaria
and other parasitic infections. It is not used
routinely now for this purpose because of
resistance by the parasites.
It is not clear how hydroxychloroquine
works in inflammatory conditions; however
it is thought to have an action on the
immune system. In rheumatoid arthritis, this
action helps to reduce inflammation and
thus reduce pain and swelling. It also limits
damage to the joints and helps to prevent
disability in the long term.
Because hydroxychloroquine acts to reduce
the damage to the joints, rather than just
relieve the pain, it belongs to the group of
medicines called disease modifying
antirheumatic drugs (DMARDs).
How is hydroxychloroquine
taken?
Hydroxychloroquine is taken by mouth in
tablet form. The usual dose is one tablet
(200mg) once or twice a day. Tablets can be
taken altogether, once a day.
The dose may be reduced to a maintenance
dose after a few months once a response is
achieved. Occasionally it may be taken
every second day.
It is best taken with food as it has a slightly
bitter taste.
Hydroxychloroquine may be used with
other arthritis medicines including:
other DMARDs such as methotrexate
steroid medicines such as prednisolone
or cortisone injections into the joint
anti-inflammatory medicines (NSAIDs)
such as naproxen (Naprosyn) and
ibuprofen (Brufen, Nurofen)
simple pain medicines such as
paracetamol.
Questions?
The information in this sheet has been obtained from various sources and has been reviewed by the Australian Rheumatology Association. It is
intended as an educational aid and does not cover all possible uses, actions, precautions, side effects, or interactions of the medicines
mentioned. This information is not intended as medical advice for individual problems nor for making an individual assessment of the risks and
benefits of taking a particular medicine. It can be reproduced in its entirety but cannot be altered without permission from the ARA.
The NHMRC publication: How to present the evidence for consumers: preparation of consumer publications (2000) was used as a guide in
developing this publication.
hydroxychloroquine